UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
![]() |
|||||||
|
Fusion Protein:SMEK2-ALK |
Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: SMEK2-ALK | FusionPDB ID: 84049 | FusionGDB2.0 ID: 84049 | Hgene | Tgene | Gene symbol | SMEK2 | ALK | Gene ID | 57223 | 238 |
Gene name | protein phosphatase 4 regulatory subunit 3B | ALK receptor tyrosine kinase | |
Synonyms | FLFL2|PP4R3B|PSY2|SMEK2|smk1 | CD246|NBLST3 | |
Cytomap | 2p16.1 | 2p23.2-p23.1 | |
Type of gene | protein-coding | protein-coding | |
Description | serine/threonine-protein phosphatase 4 regulatory subunit 3BSMEK homolog 2, suppressor of mek1 | ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | . | Q96BT7 | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000272313, ENST00000345102, ENST00000407823, ENST00000477749, | ENST00000498037, ENST00000389048, ENST00000431873, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 8 X 6 X 8=384 | 56 X 74 X 20=82880 |
# samples | 8 | 57 | |
** MAII score | log2(8/384*10)=-2.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(57/82880*10)=-7.18391827352181 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: SMEK2 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | SMEK2(55804451)-ALK(29940563), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | SMEK2-ALK seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. SMEK2-ALK seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. SMEK2-ALK seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. SMEK2-ALK seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | ALK | GO:0016310 | phosphorylation | 9174053 |
Tgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Gene Sample Information |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | READ | TCGA-F5-6864-01A | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - |
ChimerDB4 | READ | TCGA-F5-6864 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - |
Top |
Fusion ORF Analysis |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000272313 | SMEK2 | chr2 | 55804451 | - | ENST00000389048 | ALK | chr2 | 29940563 | - | 6484 | 1838 | 178 | 6033 | 1951 |
ENST00000272313 | SMEK2 | chr2 | 55804451 | - | ENST00000431873 | ALK | chr2 | 29940563 | - | 2524 | 1838 | 178 | 2523 | 782 |
ENST00000407823 | SMEK2 | chr2 | 55804451 | - | ENST00000389048 | ALK | chr2 | 29940563 | - | 6493 | 1847 | 187 | 6042 | 1951 |
ENST00000407823 | SMEK2 | chr2 | 55804451 | - | ENST00000431873 | ALK | chr2 | 29940563 | - | 2533 | 1847 | 187 | 2532 | 782 |
ENST00000345102 | SMEK2 | chr2 | 55804451 | - | ENST00000389048 | ALK | chr2 | 29940563 | - | 6554 | 1908 | 152 | 6103 | 1983 |
ENST00000345102 | SMEK2 | chr2 | 55804451 | - | ENST00000431873 | ALK | chr2 | 29940563 | - | 2594 | 1908 | 152 | 2593 | 814 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000272313 | ENST00000389048 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.000927823 | 0.9990722 |
ENST00000272313 | ENST00000431873 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.001055962 | 0.9989441 |
ENST00000407823 | ENST00000389048 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.000933559 | 0.9990664 |
ENST00000407823 | ENST00000431873 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.001044574 | 0.99895537 |
ENST00000345102 | ENST00000389048 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.00083281 | 0.9991672 |
ENST00000345102 | ENST00000431873 | SMEK2 | chr2 | 55804451 | - | ALK | chr2 | 29940563 | - | 0.000684193 | 0.99931586 |
Top |
Fusion Amino Acid Sequences |
![]() |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >84049_84049_1_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000272313_ALK_chr2_29940563_ENST00000389048_length(amino acids)=1951AA_BP=551 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD NIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEAS QMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVL QGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFY CNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLV ENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERN PNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKN TMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLI IAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCS SGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGV SCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLK EVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELM AGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCA MLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAII LERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP -------------------------------------------------------------- >84049_84049_2_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000272313_ALK_chr2_29940563_ENST00000431873_length(amino acids)=782AA_BP=551 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD NIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGKERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP -------------------------------------------------------------- >84049_84049_3_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000345102_ALK_chr2_29940563_ENST00000389048_length(amino acids)=1983AA_BP=564 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD FFLKHYRYSWSFICTPSHSHSHSTPSSSISQDNIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECS FDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQP SGRYIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGT VLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSA TFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDN ISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSE GPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRV NRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQ EGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNC SHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPE YKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLME ALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLL TCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGR MDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERS PAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEP HDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQ -------------------------------------------------------------- >84049_84049_4_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000345102_ALK_chr2_29940563_ENST00000431873_length(amino acids)=814AA_BP=564 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD FFLKHYRYSWSFICTPSHSHSHSTPSSSISQDNIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGKERS PAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEP HDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQ -------------------------------------------------------------- >84049_84049_5_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000407823_ALK_chr2_29940563_ENST00000389048_length(amino acids)=1951AA_BP=551 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD NIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEAS QMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVL QGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFY CNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLV ENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERN PNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKN TMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLI IAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCS SGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGV SCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLK EVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELM AGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCA MLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAII LERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP -------------------------------------------------------------- >84049_84049_6_SMEK2-ALK_SMEK2_chr2_55804451_ENST00000407823_ALK_chr2_29940563_ENST00000431873_length(amino acids)=782AA_BP=551 MNLWSHGEFGPLRSRRRRHRHYCLYRLLRVRSADEVSEEAAARAVETAATMSDTRRRVKVYTLNEDRQWDDRGTGHVSSTYVEELKGMSL LVRAESDGSLLLESKINPNTAYQKQQDTLIVWSEAENYDLALSFQEKAGCDEIWEKICQVQGKDPSVEVTQDLIDESEEERFEEMPETSH LIDLPTCELNKLEEIADLVTSVLSSPIRREKLALALENEGYIKKLLQLFQACENLENTEGLHHLYEIIRGILFLNKATLFEVMFSDECIM DVVGCLEYDPALAQPKRHREFLTKTAKFKEVIPITDSELRQKIHQTYRVQYIQDIILPTPSVFEENFLSTLTSFIFFNKVEIVSMLQEDE KFLSEVFAQLTDEATDDDKRRELVNFFKEFCAFSQTLQPQNRDAFFKTLAKLGILPALEIVMGMDDLQVRSAATDIFSYLVEFSPSMVRE FVMQEAQQSDDDILLINVVIEQMICDTDPELGGAVQLMGLLRTLIDPENMLATTNKTEKSEFLNFFYNHCMHVLTAPLLTNTSEDKCEKD NIVGSNKNNTICPGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGKERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGP AVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:55804451/chr2:29940563) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
. | ALK |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its methyltransferase domain (PubMed:20123966, PubMed:20308323, PubMed:31079898). Catalyzes the last step in the formation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA (PubMed:20123966, PubMed:20308323). Has a preference for tRNA(Arg) and tRNA(Glu), and does not bind tRNA(Lys)(PubMed:20308323). Binds tRNA and catalyzes the iron and alpha-ketoglutarate dependent hydroxylation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its dioxygenase domain, giving rise to 5-(S)-methoxycarbonylhydroxymethyluridine; has a preference for tRNA(Gly) (PubMed:21285950). Required for normal survival after DNA damage (PubMed:20308323). May inhibit apoptosis and promote cell survival and angiogenesis (PubMed:19293182). {ECO:0000269|PubMed:19293182, ECO:0000269|PubMed:20123966, ECO:0000269|PubMed:20308323, ECO:0000269|PubMed:21285950, ECO:0000269|PubMed:31079898}. |
![]() |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000272313 | - | 10 | 15 | 1_100 | 503.3333333333333 | 765.0 | Domain | Note=WH1 |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000345102 | - | 11 | 17 | 1_100 | 535.3333333333334 | 850.0 | Domain | Note=WH1 |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000407823 | - | 10 | 16 | 1_100 | 503.3333333333333 | 818.0 | Domain | Note=WH1 |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 816_940 | 222.33333333333334 | 1621.0 | Compositional bias | Note=Gly-rich | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 1116_1392 | 222.33333333333334 | 1621.0 | Domain | Protein kinase | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 264_427 | 222.33333333333334 | 1621.0 | Domain | MAM 1 | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 437_473 | 222.33333333333334 | 1621.0 | Domain | Note=LDL-receptor class A | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 478_636 | 222.33333333333334 | 1621.0 | Domain | MAM 2 | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 1197_1199 | 222.33333333333334 | 1621.0 | Region | Note=Inhibitor binding | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 1060_1620 | 222.33333333333334 | 1621.0 | Topological domain | Cytoplasmic | |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 1039_1059 | 222.33333333333334 | 1621.0 | Transmembrane | Helical |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000272313 | - | 10 | 15 | 719_724 | 503.3333333333333 | 765.0 | Compositional bias | Note=Poly-Glu |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000272313 | - | 10 | 15 | 831_838 | 503.3333333333333 | 765.0 | Compositional bias | Note=Poly-Glu |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000345102 | - | 11 | 17 | 719_724 | 535.3333333333334 | 850.0 | Compositional bias | Note=Poly-Glu |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000345102 | - | 11 | 17 | 831_838 | 535.3333333333334 | 850.0 | Compositional bias | Note=Poly-Glu |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000407823 | - | 10 | 16 | 719_724 | 503.3333333333333 | 818.0 | Compositional bias | Note=Poly-Glu |
Hgene | SMEK2 | chr2:55804451 | chr2:29940563 | ENST00000407823 | - | 10 | 16 | 831_838 | 503.3333333333333 | 818.0 | Compositional bias | Note=Poly-Glu |
Tgene | ALK | chr2:55804451 | chr2:29940563 | ENST00000389048 | 0 | 29 | 19_1038 | 222.33333333333334 | 1621.0 | Topological domain | Extracellular |
Top |
Fusion Protein Structures |
![]() * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
Top |
pLDDT score distribution |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
ALK_pLDDT.png![]() |
![]() * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
Top |
Ramachandran Plot of Fusion Protein Structure |
![]() |
Fusion AA seq ID in FusionPDB and their Ramachandran plots |
Top |
Fusion Protein-Protein Interaction |
![]() |
![]() |
Gene | PPI interactors |
![]() |
Gene | STRING network |
SMEK2 | |
ALK | ![]() |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to SMEK2-ALK |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to SMEK2-ALK |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | ALK | C0007131 | Non-Small Cell Lung Carcinoma | 28 | CGI;CTD_human |
Tgene | ALK | C0027819 | Neuroblastoma | 13 | CGI;CTD_human;ORPHANET |
Tgene | ALK | C0152013 | Adenocarcinoma of lung (disorder) | 8 | CGI;CTD_human |
Tgene | ALK | C2751681 | NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 | 8 | CLINGEN;UNIPROT |
Tgene | ALK | C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 6 | CGI;CTD_human |
Tgene | ALK | C0334121 | Inflammatory Myofibroblastic Tumor | 4 | CGI;CTD_human;ORPHANET |
Tgene | ALK | C0018199 | Granuloma, Plasma Cell | 3 | CTD_human |
Tgene | ALK | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
Tgene | ALK | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
Tgene | ALK | C0238463 | Papillary thyroid carcinoma | 2 | ORPHANET |
Tgene | ALK | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
Tgene | ALK | C0006118 | Brain Neoplasms | 1 | CGI;CTD_human |
Tgene | ALK | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
Tgene | ALK | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
Tgene | ALK | C0011570 | Mental Depression | 1 | PSYGENET |
Tgene | ALK | C0011581 | Depressive disorder | 1 | PSYGENET |
Tgene | ALK | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
Tgene | ALK | C0036341 | Schizophrenia | 1 | PSYGENET |
Tgene | ALK | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
Tgene | ALK | C0085269 | Plasma Cell Granuloma, Pulmonary | 1 | CTD_human |
Tgene | ALK | C0153633 | Malignant neoplasm of brain | 1 | CGI;CTD_human |
Tgene | ALK | C0278601 | Inflammatory Breast Carcinoma | 1 | CTD_human |
Tgene | ALK | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
Tgene | ALK | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
Tgene | ALK | C0678222 | Breast Carcinoma | 1 | CTD_human |
Tgene | ALK | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
Tgene | ALK | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
Tgene | ALK | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
Tgene | ALK | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
Tgene | ALK | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
Tgene | ALK | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
Tgene | ALK | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
Tgene | ALK | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
Tgene | ALK | C1332079 | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | ORPHANET |
Tgene | ALK | C1458155 | Mammary Neoplasms | 1 | CTD_human |
Tgene | ALK | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
Tgene | ALK | C2931189 | Neural crest tumor | 1 | ORPHANET |
Tgene | ALK | C3899155 | hereditary neuroblastoma | 1 | GENOMICS_ENGLAND |
Tgene | ALK | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |